Search the Newsreel

Gevo, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GEVO) 2026-08-08

Gevo, Inc. (GEVO) published its Q2 2026 earnings call presentation on August 8, 2026. The company reported an EPS of -$0.01, which beat estimates by $0.00, and a revenue of $46.50M, a 7.11% year-over-year increase, beating expectations by $1.42M. The slide deck was released …

Evolent Health (NYSE:EVH) Announces Quarterly Earnings Results

Gevo (NASDAQ:GEVO) Releases Earnings Results, Beats Estimates By $0.01 EPS

Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next

Revolution Medicines (RVMD) reported a significant net loss in Q2 2026, yet its stock rose by 9.4% due to advancing daraxonrasib through FDA review for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have received daraxonrasib, indicating strong real-world interest, and …

Gevo, Inc. (GEVO) executive sells 10,257 shares to cover award withholding

Kimberly T. Bowron, Chief of Staff at Gevo, Inc. (GEVO), sold 10,257 shares of common stock on August 6, 2026, at an average price of $1.5458 per share. This sale was conducted under a Rule 10b5-1 trading plan to cover withholding obligations arising from …

Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside

Evommune, Inc.'s average 12-month price target has been reduced to $30.11 from $32.89 by 9 analysts, with individual forecasts ranging from $22 to $50 per share. This new target implies a potential upside of approximately 125% from its Aug. 6 closing price. The consensus …

Gevo CEO Paul Bloom sells $48,068 in company shares

Gevo CEO Paul Bloom sold 31,096 shares of company common stock worth $48,068 to cover tax withholding obligations from a restricted stock award. Following the transaction, Bloom directly holds 1,452,303 shares. The company recently reported better-than-expected Q2 2026 results, with a narrower loss, increased …

Noticias de acciones de Devon Energy Corp (DVN)

Kwmg LLC Purchases 165,201 Shares of Devon Energy Corporation $DVN

Kwmg LLC significantly increased its stake in Devon Energy Corporation, purchasing an additional 165,201 shares, nearly doubling its previous position to 336,207 shares valued at $13.9 million. This comes as Devon Energy reported strong quarterly results, exceeding revenue and earnings expectations, and declared a …

Gevo, Inc. (NASDAQ:GEVO) Given Consensus Rating of "Hold" by Brokerages

Gevo, Inc. (NASDAQ:GEVO) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $2.875 compared to its recent price of $1.57. Despite beating Q2 revenue and EPS estimates and projecting over $60 million in adjusted EBITDA for 2026, concerns …

Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Analysts have given Evommune, Inc. (NYSE:EVMN) a "Moderate Buy" consensus rating, with an average 12-month price target of $43.25, significantly above its current trading price of $14.14. Despite missing recent EPS estimates, the company has seen new institutional investment and insider selling over the …

Evolent Health (EVH) Stock Rebounds As Growth Momentum Confronts Losses

Evolent Health (EVH) stock jumped 10% after its Q2 report, showcasing significant revenue growth despite persistent net losses. The company's future hinges on balancing its multi-year revenue expansion from Performance Suite contracts and automation with its ongoing profitability challenges and a low valuation. Investors …

Evolus Inc (EOLS) Stock News Today

This page provides an overview of Evolus Inc (EOLS) stock news, earnings, analyst ratings, and key developments. It notes the current stock price, market cap, and indicates that more news will be coming soon. The page serves as a hub for investors to track …

Evotec AG (NASDAQ:EVO) Receives Consensus Recommendation of "Hold" from Brokerages

Evotec AG (NASDAQ:EVO) has received a consensus "Hold" recommendation from five brokerages, with an average 12-month price target of $3.00. The ratings include two "Buy," two "Hold," and one "Sell," reflecting cautious sentiment. Recent analyst actions have shown mixed views, with some downgrades and …

Evolent Health Q2 Earnings Call Highlights

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …

EMAT Q1 2026 Earnings: Steep Loss Per Share Collides With a 4.46% Stock Advance - Revenue Estimate Trend

Devon Energy (DVN) Stock Still Looks Discounted After Q2 Profit And Dividend News

Gevo (GEVO) Stock Cheers EBITDA Outlook As Impairment Clouds Profit Picture

Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen

Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $14.50. Shares of Evolus opened at $7.59, a 2.4% increase, and are nearing their 12-month high. …

Devon Energy Q2 Earnings Call Highlights

Key Points Interested in Devon Energy Corporation? Here are five stocks we like better. Devon exceeded Q2 guidance, generating $1.7 billion in adjusted free cash flow while beating targets for oil production, total production, operating costs and capital spending. The company tightened its 2026 …

Could CSL (ASX:CSL), QBE and Evolution Mining Be ASX Income Opportunities Worth Watching?

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. announced its second quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects to report top-line data for its EVO756 atopic dermatitis (AD) Phase 2b trial in September 2026 and has initiated a Phase 2b trial for EVO756 …

Evotec SE (EVO) Aktuelle Aktien-News

Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 171st out of 387 in its industry. Analysts have set an average price target of $2.50, with a consensus "Buy" rating based on one analyst. The company's expected revenue for the next …

Gevo, Inc. (GEVO) CFO sells 18,223 shares in Rule 10b5-1 plan trade

Gevo, Inc.'s CFO, Agiri Oluwagbemileke Yusuf, sold 18,223 shares of common stock on August 6, 2026, at a weighted average price of $1.5384 per share through a pre-arranged Rule 10b5-1 trading plan. After the sale, he directly beneficially owns 472,893 shares and indirectly holds …

Gevo Inc Earnings Call: Growth, Credits and Risks

Gevo Inc. reported its Q2 2026 earnings, showcasing revenue growth, surging gross profits, and a doubled adjusted EBITDA outlook for 2026. The company's strategy heavily relies on carbon credits, tax incentives, and project financing, which also introduce execution risks despite strong operational momentum. Key …

Northland Securities Maintains Gevo Inc(GEVO.US) With Buy Rating, Maintains Target Price $3.75

Northland Securities has reiterated its Buy rating on Gevo Inc (GEVO.US) and maintained its target price of $3.75. This continued positive outlook from the firm suggests confidence in Gevo's future performance.

Evogene Ltd. (EVGN) investor group boosts ownership to 15.98%

An investor group linked to L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman, and Ron Yair Peled has increased its stake in Evogene Ltd. (EVGN) to approximately 15.98% of the outstanding ordinary shares. This increase follows open-market purchases of 216,300 American …

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

Revolution Medicines is preparing for the potential launch of its pancreatic cancer drug, daraxonrasib. The Redwood City-based company, led by CEO Mark Goldsmith, boasts a substantial financial reserve of $3.9 billion in cash and equivalents, positioning it strongly among mid-size biotechs for this significant …

Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases

Evotec SE and Odyssey Therapeutics Inc. have announced a strategic AI-enabled R&D collaboration aimed at discovering new small molecule treatments for autoimmune and inflammatory diseases. The partnership combines Odyssey's disease biology expertise with Evotec's integrated discovery platform, advanced screening technologies, and proprietary compound libraries. …

Análise e Previsão das Ações da Devon Energy Corp (DVN)

RVLV Q2 Beat Masks Tariff Boost as 2026 Investment Spending Rises

Revolve Group, Inc. RVLV beat second-quarter earnings expectations as sales growth stayed broad and underlying merchandising economics improved. Yet tariff refunds amplified reported profitability, making the quality of the margin gain an important part of the quarter. Management is also spending more on long-term …

Is RVLV Stock a Buy as Growth Accelerates but Valuation Stays Rich?

Revolve Group, Inc. RVLV is showing better operating momentum, with faster demand, customer growth and broad-based gains across its businesses. The question is whether that improvement is enough to justify a premium valuation. Investors also have to weigh elevated spending, inventory growth and tariff-related …

RVLV Surges 33.1% in Three Months: Can Its Momentum Keep Building?

Revolve Group, Inc. RVLV shares have climbed 33.1% over the past three months, bringing the durability of the rally into focus. The move has coincided with faster sales growth, customer gains and better underlying merchandise margins. The operating backdrop is improving, but the stock …

Evolution Global Acquisition Ord Shs Class A (EVOX) Stock News Today

Evolution Global Acquisition Ord Shs Class A (EVOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Evolution Global Acquisition Ord Shs Class A (EVOX), detailing future EPS and revenue growth estimates. It includes a stock overview with market capitalization and current stock price, along with a peer comparison. The forecast also covers expected …